中期18FFDG PET-CT在淋巴瘤中的应用

doi:10.3760/cma.j.issn.1673-422X.2015.06.020

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (6): 472-474.doi: 10.3760/cma.j.issn.1673-422X.2015.06.020

中期¹⁸FFDG PET-CT在淋巴瘤中的应用

张玥伟,王雪鹃,杨志,朱军

100142恶性肿瘤发病机制及转化研究教育部重点实验室北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科（张玥伟、王雪鹃、杨志），淋巴肿瘤内科（朱军）

收稿日期:2014-12-17 出版日期:2015-06-08 发布日期:2015-05-31
通讯作者: 王雪鹃，Email：xuejuan_wang@hotmail.com E-mail:xuejuan_wang@hotmail.com

Application of interim ^18FFDG PET-CT in lymphoma

Zhang Yuewei, Wang Xuejuan, Yang Zhi, Zhu Jun

Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education & Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China

Received:2014-12-17 Online:2015-06-08 Published:2015-05-31
Contact: Wang Xuejuan E-mail:xuejuan_wang@hotmail.com

摘要/Abstract

摘要： 中期^18FFDG PET-CT能提供代谢功能和形态学的双重信息，成为评估淋巴瘤患者疗效及其预后最为敏感的手段，也成为指导临床试验设计及改变临床应用的依据。目前，如何合理化应用中期^18FFDG PET-CT仍存在争议。

关键词: 正电子发射断层显像术, 淋巴瘤, 预后, 中期

Abstract: Interim fluorine 18 fluorodeoxyglucose (^18FFDG) positron emission tomography (PET) integrated with computed tomography (CT) provides both metabolic and morphologic information, which becomes one of the most sensitive tools to evaluate the efficacy of the therapy and predict the prognosis of patients with lymphoma. Meanwhile, it is the basis for guiding trial design and changing clinical practice. However, it is still a controversial issue in the ideal utilization of interim ^18FFDG PET-CT imaging for the patients with lymphoma.

Key words: Positron emission tomography, Lymphoma, Prognosis, Metaphase

张玥伟,王雪鹃,杨志,朱军. 中期¹⁸FFDG PET-CT在淋巴瘤中的应用[J]. 国际肿瘤学杂志, 2015, 42(6): 472-474.

Zhang Yuewei, Wang Xuejuan, Yang Zhi, Zhu Jun. Application of interim ^18FFDG PET-CT in lymphoma[J]. Journal of International Oncology, 2015, 42(6): 472-474.

参考文献

［1］ Itti E, Meignan M, BerrioloRiedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large Bcell lymphoma: comparison between Deauville criteria and ΔSUVmax［J］. Eur J Nucl Med Mol Imaging, 2013, 40(9): 1312-1320. ［2］ Dupuis J, BerrioloRiedinger A, Julian A, et al. Impact of ［(18)F］fluorodeoxyglucose positron emission tomography response evaluation in patients with hightumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d′Etudes des Lymphomes de l′Adulte and GOELAMS［J］. J Clin Oncol, 2012, 30(35): 4317-4322. ［3］ Casasnovas RO, Meignan M, BerrioloRiedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B cell lymphoma［J］. Blood, 2011, 118(1): 37-43. ［4］ Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group［J］. J Clin Oncol, 2014, 32(27): 3048-3058. ［5］ Gallamini A, Zwarthoed C, Borra A. Positron emission tomography (PET) in Oncology［J］. Cancers (Basel), 2014, 6(4): 1821-1889. ［6］ Kostakoglu L, Cheson BD. Stateoftheart research on "lymphomas: role of molecular imaging for staging, prognostic evaluation, and treatment response"［J］. Front Oncol, 2013, 3: 212. ［7］ Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin′s disease［J］. Haematologica, 2006, 91(4): 475-481. ［8］ Zinzani PL, Rigacci L, Stefoni V, et al. Early interim 18FFDG-PET in Hodgkin′s lymphoma: evaluation on 304 patients［J］. Eur J Nucl Med Mol Imaging, 2012, 39(1): 4-12. ［9］ Iltis A, Eder V, Blasco H, et al. Decisional early interim FFluoro2DeoxyDGlucose positron emission tomography after two cycles of chemotherapy in de novo Hodgkin lymphoma［J］. Acta Haematol, 2015, 133(2): 172-178. ［10］ Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advancedstage Hodgkin lymphoma patients with a interimPET positive after two ABVD courses［J］. Br J Haematol, 2011, 152(5): 551-560. ［11］ Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomographynegative stage Ⅰ/Ⅱ Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial［J］. J Clin Oncol, 2014, 32(12): 1188-1194. ［12］ Lin C, Itti E, Haioun C, et al. Early 18F FDG-PET for prediction of prognosis in patients with diffuse large Bcell lymphoma: SUVbased assessment versus visual analysis［J］. J Nucl Med, 2007, 48(10): 1626-1632. ［13］ Kim J, Hong J, Kim SG, et al. Prognostic value of metabolic tumor volume estimated by (18) F FDG positron emission tomography/computed tomography in patients with diffuse large B cell lymphoma of stage Ⅱ or Ⅲ disease［J］. Nucl Med Mol Imaging, 2014, 48(3): 187-195. ［14］ Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B cell lymphoma［J］. Cancer, 2013, 119(6): 1195-1202. ［15］ TychyjPinel C, Ricard F, Fulham M, et al. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study［J］. Eur J Nucl Med Mol Imaging, 2014, 41(3): 408-415. ［16］ Pellegrini C, Argnani L, Broccoli A, et al. Prognostic value of interim positron emission tomography in patients with peripheral T cell lymphoma［J］. Oncologist, 2014, 19(7): 746-750. ［17］ Li YJ, Li ZM, Xia XY, et al. Prognostic value of interim and post therapy 18FFDG-PET/CT in patients with mature T cell and natural killer cell lymphomas［J］. J Nucl Med, 2013, 54(4): 507-515. ［18］ González Barca E, Canales M, Cortés M, et al. Predictive value of interim 18F FDG-PET/CT for eventfree survival in patients with diffuse large B cell lymphoma homogenously treated in a phase Ⅱ trial with six cycles of R-CHOP 14 plus pegfilgrastim as first line treatment［J］. Nucl Med Commun, 2013, 34(10): 946-952.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[5]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫. 原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[6]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[7]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[8]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[9]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[10]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[11]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[12]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[13]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[14]	黄镇, 陈永顺. 循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[15]	王潇, 李盈, 罗玉杰, 晋舒. 基于列线图模型探讨血清学指标对鼻咽癌预后的判断价值[J]. 国际肿瘤学杂志, 2023, 50(8): 463-469.

中期¹⁸FFDG PET-CT在淋巴瘤中的应用

Application of interim ^18FFDG PET-CT in lymphoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价